3.37  0.13 (4.01%)		10-25 16:00
Open: 3.4268 High: 3.448 Volume: 27,682		Pre. Close: 3.24 Low: 3.2 Market Cap: 34(M)

Short term
Mid term
Targets	6-month :	4.92	1-year :	5.79
Resists	First :	4.21	Second :	4.96
Pivot price	3.9
Supports	First :	3	Second :	2.5
MAs	MA(5) :	3.84	MA(20) :	3.76
	MA(100) :	3.03	MA(250) :	2.99
MACD	MACD :	0.1	Signal :	0.1
%K %D	K(14,3) :	38.7	D(3) :	36.7
RSI	RSI(14): 53.6
52-week	High :	4.96	Low :	1.98

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ACST ] has closed above bottom band by 44.0%. Bollinger Bands are 86.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	4.18 - 4.2	4.2 - 4.21
Low:	3.78 - 3.81	3.81 - 3.82
Close:	3.8 - 3.83	3.83 - 3.86

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Fri, 25 Oct 2024
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. - GlobeNewswire

Wed, 25 Jan 2023
Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule - FinancialContent

Mon, 10 May 2021
Reed Smith represents Grace Therapeutics in signing of a merger agreement with Acasti Pharma - Reed Smith LLP

Mon, 11 Jan 2021
Thinking about buying stock in Sundial Growers, Acasti Pharma, Transenterix, Jaguar Health, or Marathon Patent Group? - PR Newswire

Mon, 13 Jan 2020
Acasti Pharma placed under review by Mackie Research Capital - Cantech Letter

Mon, 18 Nov 2019
Acasti Pharma's omega-3 drug CaPre shows potential use as type 2 diabetes treatment - Proactive financial news

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	10 (M)
Shares Float	5 (M)
Held by Insiders	38.3 (%)
Held by Institutions	21.2 (%)
Shares Short	154 (K)
Shares Short P.Month	4 (K)

EPS	-1.43
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.86
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-11.7 %
Return on Equity (ttm)	-18.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.31
Qtrly Earnings Growth	0 %
Operating Cash Flow	-10 (M)
Levered Free Cash Flow	-6 (M)

PE Ratio	-2.68
PEG Ratio	0
Price to Book value	0.65
Price to Sales	0
Price to Cash Flow	-4.01

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.